Parcom Capital has acquired clinical research organization Viroclinics Biosciences. The acquisition will give Viroclinics the opportunity to expand its fields of expertise and its portfolio of services.
Viroclinics was founded in 2001 and specializes in testing new vaccines and drugs in the clinical trial stages prior to market launch. Viroclinics has clients across the globe and conducts virology testing for clients that include the world's top 10 biopharmaceutical companies. Viroclinics tests about 90 percent of all anti-influenza medications developed worldwide. The company expects to see further growth in other fields of virology in the coming years.
"Our main focus at the moment is the research and treatment of respiratory viruses. We would like to broaden our portfolio, especially in the area of other viral targets, such as hepatitis, polio and RSV. For instance, we are very closely involved in a project that is on the verge of eradicating the polio virus for good,” Bob van Gemen, CEO Viroclinics Biosciences said. “In Parcom Capital, we have found a new, solid partner who will enable us to realize even more of our ambitious targets. In the coming years, we will enter a new phase as a company and we have major growth ambitions."
As a result of the sale, Viroclinics is now fully owned by Parcom Capital and management.
Gilde Healthcare Service is the selling party and was advised in the acquisition process by William Blair. Parcom was advised by PricewaterhouseCoopers. The acquisition has no consequences for the employees of Viroclinics. The parties decline to publish any financial details.